ProCE Banner Activity

MET Exon 14 Mutation–Positive NSCLC: FAQ Part 2

Podcast Episodes
Listen to international lung cancer experts Luis Paz-Ares, MD, PhD; D. Ross Camidge, MD, PhD; and Karen L. Reckamp, MD, MS, as they answer audience questions from a live CCO Webinar on METex14 mutation–positive NSCLC, from guidance on biomarker testing to sequencing of immunotherapy with MET inhibitors in these patients.

Released: August 28, 2020

Expiration: August 27, 2021

Share

Faculty

Karen L. Lindsay

Karen L. Lindsay, MD

Associate Professor of Medicine
Gastroenterology and Liver Disease
Keck School of Medicine
Hepatitis Research & Treatment Center
University of Southern California
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

This educational activity is supported by an independent grant from the Healthcare business of

Merck KGaA

Faculty Disclosure

Primary Author

Karen L. Lindsay, MD

Associate Professor of Medicine
Gastroenterology and Liver Disease
Keck School of Medicine
Hepatitis Research & Treatment Center
University of Southern California
Los Angeles, California

Karen L. Reckamp, MD, MS, has disclosed that she has received consulting fees from AstraZeneca, Boehringer Ingelheim, Calithera, Genentech, Guardant, Precision Health, and Tesaro and funds for research support paid to her prior institution from AbbVie, Acea, Adaptimmune, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Guardant, Janssen, Loxo Oncology, Molecular Partners, Seattle Genetics, Spectrum, Takeda, Xcovery, and Zeno.

Staff Disclosure

Staff

Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin L. Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.